Skip to main content

Advertisement

Table 2 Baseline patient characteristics

From: Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

  RCT CZP (n = 1224) All CZP (n = 1506)
Female sex, n (%) 1008 (82.4) 1245 (82.7)
Age, years, n (%) <50 470 (38.4) 580 (38.5)
≥50 to < 60 440 (35.9) 546 (36.3)
≥60 to < 70 247 (20.2) 300 (19.9)
≥70 67 (5.5) 80 (5.3)
Disease duration (years), n (%) <2 261 (21.3) 323 (21.4)
≥2 963 (78.7) 1183 (78.6)
DAS28(CRP), mean (SD) 6.20 (0.83) 6.20 (0.85)
HAQ-DI, mean (SD) 1.65 (0.60) 1.65 (0.60)
CRP, mg/L, median (IQR) 15.0 (6.0–32.0) 15.0 (6.0–32.0)
Rheumatoid factor, IU/ml, median (IQR) 68.3 (18.9–201.1) 70.0 (19.4–200.0)
mTSS, median (IQR) 20.0 (5.5–54.7) 20.0 (6.0–55.0)
BMI, kg/m2, n (%) <20 83 (6.8) 104 (6.9)
20–30 833 (68.1) 1024 (68.0)
>30 308 (25.2) 378 (25.1)
Glucocorticoid dose, mg/day, n (%) 0 518 (42.3) 637 (42.3)
>0–5 332 (27.1) 402 (26.7)
>5 374 (30.6) 467 (31.0)
Systemic MTX dose, mg/week, n (%) ≤15 1018 (83.2) 1261 (83.7)
>15 206 (16.8) 245 (16.3)
Medically treated comorbidities, n (%)a   
 Diabetes mellitus 47 (3.8) 53 (3.5)
 COPD/asthma 34 (2.8) 38 (2.5)
 Cardiac disorderb 15 (1.2) 17 (1.1)
 Hypertensionc 387 (31.6) 465 (30.9)
 Hyperlipidemia 55 (4.5) 66 (4.4)
 Thyroid disorder 55 (4.5) 63 (4.2)
 Osteoporosis 92 (7.5) 113 (7.5)
 Depression 37 (3.0) 45 (3.0)
  1. Abbreviations: CZP Certolizumab pegol, RCT Randomized controlled trial, DAS28(CRP) 28-joint Disease Activity Score with C-reactive protein, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, mTSS Modified total Sharp score, MTX Methotrexate, BMI Body mass index, COPD Chronic obstructive pulmonary disease, RCT CZP Patients randomized to CZP in the RAPID1/RAPID2 randomized controlled trials, All CZP All patients treated with CZP during the RAPID1/RAPID2 randomized controlled trials and/or open label extensions
  2. aMedically treated comorbidities were identified on the basis of patients’ medical histories and medications at baseline
  3. bCardiac disorder included coronary artery disease and heart failure
  4. cHypertension included patients with history of cerebrovascular disorder (n = 5 in RCT CZP and n = 5 in All CZP) and transient ischemic attack (n = 4 in RCT CZP and n = 5 in All CZP)